What is ISOThrive?
ISOThrive Inc. is a clinical-stage biotech firm specializing in microbiome therapeutics designed to combat chronic diseases stemming from microbiome dysbiosis. The company leverages proprietary digestion-resistant carbohydrates, notably maltosyl-isomaltooligosaccharide (MIMO), to selectively target beneficial bacteria and restore microbial balance. Their primary asset, ISOT-101, is currently undergoing Phase 2 clinical trials, with initial therapeutic targets including gastroesophageal reflux disease (GERD), irritable bowel syndrome with constipation (IBS-C), and functional dyspepsia. ISOThrive employs advanced platforms for accelerated carbohydrate drug discovery and precision medicine, enabling the creation of personalized therapeutic solutions for various gastrointestinal conditions.
How much funding has ISOThrive raised?
ISOThrive has raised a total of $1.4M across 1 funding round:
Unspecified
$1.4M
Unspecified (2014): $1.4M, investors not publicly disclosed
What's next for ISOThrive?
With the recent major strategic investment, ISOThrive is poised to accelerate the development and clinical validation of its microbiome-based therapies. The company's focus on proprietary carbohydrate technology and precision medicine positions it to address significant unmet needs in the treatment of chronic gastrointestinal disorders. Future endeavors will likely concentrate on advancing ISOT-101 through its Phase 2 study and potentially initiating further clinical programs, supported by the substantial capital raised. This strategic financing is expected to bolster research and development efforts, expand the company's scientific team, and facilitate the progression towards commercialization.
See full ISOThrive company page
